Navigation Links
Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
Date:11/5/2008

ncer assay, our narrowing net loss, and our strong balance sheet attest to the strength of our business model as we deliver the promise of genomics into the practice of medicine."

Additional Third Quarter 2008 Financial Results

The majority of product revenue, approximately 52 percent, was recorded on an accrual basis and recognized at the time the test results were delivered during the third quarter of 2008, reflecting established payment patterns from payors with coverage policies in place.

Total operating expenses were $31.4 million in the third quarter of 2008, compared with $24.0 million for the third quarter of 2007. Included in third quarter 2008 operating expenses were non-cash charges of $3.6 million, including $2.3 million of stock-based compensation expense, compared with $1.6 million in the same period in 2007, and $1.3 million of depreciation and amortization expenses, compared with $1.0 million in the same period in 2007.

Financial Results for Nine Months Ended September 30, 2008

Total revenue for the nine months ended September 30, 2008 was $79.3 million, compared with $44.7 million for the first nine months of 2007. Product revenue for the nine months ended September 30, 2008 was $77.8 million, compared with $43.5 million for the first nine months of 2007. Contract revenue constituted the balance of revenue for the first nine months of 2008 and 2007.

Net loss for the nine months ended September 30, 2008 was $13.8 million, compared with $21.3 million for the first nine months of 2007. Basic and diluted net loss per share was $0.49 for the nine months ended September 30, 2008, compared with a net loss per share of $0.81 for the first nine months of 2007.

Total operating expenses for the nine months ended September 30, 2008 were $94.2 million, compared with $67.6 million for the comparable period in 2007. The increase in expenses includes non-cash charges of $10.5 million, including stock-based compensati
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014   ISN ... & Safety Performance Indicators publication series. With ... of activity reported in 2013 within its online contractor ... and safety key performance indicator (KPI) statistics. ... Clients, U.S. publication is available in two ...
(Date:12/17/2014)... Based on the revenues gained from ... is dominated by four major players contributing to ... players include GE Healthcare (U.K.), Siemens AG (Germany), ... Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , ... attributed to its strong product portfolio, which includes ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2
... Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN)( ... Inc., its wholly owned subsidiary, announced today they have ... Army Medical Research and Materiel Command (USAMRMC) for consideration ... stem cells (ASCs) harvested from liposuction for treating Traumatic ...
... PARSIPPANY, N.J., May 4 Arno Therapeutics, Inc. (OTC ... oncology therapeutics, today announced that it has voluntarily filed ... ("SEC") in order to deregister its common stock under ... a result, effective immediately, Arno,s obligation to file periodic ...
... Develop Powerful Tools for Detecting Ovarian Cancer Earlier FRANKLIN ... (Becton, Dickinson and Company) (NYSE: BDX ) ... a worldwide development and supply agreement for oncology diagnostic ... develop diagnostic products that incorporate Fujirebio Diagnostics, cancer biomarkers ...
Cached Biology Technology:Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 3BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 2BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 3BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 4
(Date:11/21/2014)... Nov. 20, 2014 Strict laws against distracted ... piloting the North American and European automotive sector towards ... gesture recognition systems that are intuitive and able to ... the industry. New analysis from Frost ... Market in Europe and ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
(Date:11/12/2014)... 12, 2014 Crossmatch™, a leading provider of ... ® fingerprint readers have been deployed throughout Montparnasse ... Central Mexico . The bakery chain implemented the ... issues caused by employees clocking in for each other. ... readers, Montparnasse relied on paper timecards and a mechanical ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... infects more than 170 million people worldwide. Approximately 80 ... cirrhosis, cancer and also hepatic iron overload. A new ... School of Medicine reveals that HCV not only alters ... 1 (TfR1) but that TfR1 also mediates HCV entry. ...
... For more than a decade, scientists have suspected that hairpin-shaped ... scientists at NC State University have found the first example ... The research, published online in Proceedings of the ... describes how one strand of micro-RNA reduced by more than ...
... and the Woodrow Wilson International Center for Scholars are ... Foundation (NSF) to help realize potential benefits and to ... The grant is supported jointly by three units ... the Division of Environmental Biology, and the Engineering Directorate. ...
Cached Biology News:New Loyola study on hepatitis C virus entry factor 2